P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY
Pinkal Desai(NewYork–Presbyterian Hospital), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Ian W. Flinn(Tennessee Oncology), Jamal Saeh(AstraZeneca (Brazil)), Susan O’Brien(University of California, Irvine), Margaret Wey(The University of Texas at San Antonio Health Science Center), Raoul Tibes(BioNTech (Germany)), Javid J. Moslehi(Cardiovascular Institute of the South), Sagar Lonial(Emory University), Shringi Sharma(AstraZeneca (United Kingdom)), Mary Liu(AstraZeneca (United Kingdom)), Damilola Olabode(AstraZeneca (United Kingdom)), Neha Korde(United States Fish and Wildlife Service), James S. Blachly(The Ohio State University Wexner Medical Center), Patricia Cheung(AstraZeneca (United Kingdom)), Hong Chen(AstraZeneca (United Kingdom)), Amanda F. Cashen(MACOM (United States)), Marcio Andrade(AstraZeneca (United Kingdom)), Jacqueline S. Garcia(Dana-Farber Cancer Institute), Firasath Ali Syed(AstraZeneca (United Kingdom)), Manali Kamdar(University of Colorado Cancer Center)
Cited by 6
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k